AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out daily tasks such as eating and walking, months after the drugmaker disclosed its success in a separate study.
Researchers at the Foundation have uncovered new insights into the complex link between dopamine and rest tremor in Parkinson ...
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...
Parkinson’s disease is a progressive neurological disorder in which ongoing changes in the brain affect and interfere with ...
Two teams of scientists have recently come up with potential breakthroughs with preventing a serious side effect of Parkinson ...
Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
The following is a summary of “Association of Striatal Dopamine Depletion and Brain Metabolism Changes With Motor and ...
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.
Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback